Normosang (Human Hemin)

Human Hemin, the active ingredient in Normosang, is a heme (heme analog) presented as an injectable solution for intravenous use. It is employed to treat acute intermittent porphyria and other acute hepatic porphyrias by supplying exogenous heme during attacks, helping to normalize heme‑dependent enzymatic pathways.

GNH USA supplies Normosang as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and specialty clinics worldwide, ensuring quality‑controlled delivery, regulatory compliance, and reliable cold‑chain logistics across global markets for acute care and research purposes.

Normosang acts on the heme biosynthesis pathway to manage acute porphyria attacks.

Acute intermittent porphyria: reduces the severity and duration of acute attacks by restoring heme feedback inhibition. Acute hepatic porphyria (non‑AIP): alleviates symptoms such as abdominal pain and neuro‑visceral manifestations during crises. Porphyria‑induced neurotoxicity: helps prevent progression of neurological complications by decreasing toxic porphyrin precursors.

Human Hemin may be associated with a range of adverse reactions, varying from mild infusion‑related events to rare serious complications.

Common Side Effects: - Infusion site pain: discomfort or burning at the injection site. - Fever or chills: transient temperature elevation during or after infusion. - Nausea or vomiting: gastrointestinal upset following administration. - Headache or hypertension: mild increase in blood pressure or head pain.

Serious or Rare Side Effects: - Anaphylactic reaction: severe allergic response requiring immediate medical intervention. - Hemolysis in G6PD‑deficient patients: rapid destruction of red blood cells. - Acute renal failure: sudden loss of kidney function, especially with high‑dose or prolonged therapy.

When using Normosang, several precautions should be observed to ensure patient safety.

Assess G6PD deficiency: avoid use in patients with known deficiency due to hemolysis risk. Monitor liver function: hemin may affect hepatic enzymes, requiring periodic testing. Check renal function: patients with pre‑existing kidney disease need close observation. Avoid rapid infusion: administer over recommended period to reduce cardiovascular stress. Pregnancy and lactation: safety not established; use only if benefit outweighs risk. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Human Hemin can interact with other medicines, necessitating careful review of a patient's medication list.

Major Interactions (Avoid): - Porphyrinogenic drugs (e.g., barbiturates, sulfonamides, antiepileptics): can precipitate attacks despite hemin therapy. - Concurrent heme preparations: may cause excess iron load and toxicity. - Vitamin K antagonists (warfarin): hemin may potentiate anticoagulant effect, increasing bleeding risk.

Moderate Interactions (Monitor Closely): - CYP450 inducers (e.g., rifampicin, carbamazepine): may reduce hemin efficacy. - Iron supplements: can increase iron burden, monitor ferritin levels. - Antihypertensive agents: hemin‑induced hypertension may require dose adjustment.